Correct Answer: D. Hepatic parenchymal copper concentration
The clinical presentation — jaundice, fatigue, muscle stiffness, tremors, behavioral changes, hepatosplenomegaly, and Kayser-Fleischer rings — is classic for Wilson's disease (hepatolenticular degeneration), an autosomal recessive disorder caused by mutations in the ATP7B gene encoding a copper-transporting ATPase. Defective biliary copper excretion leads to toxic copper accumulation in the liver, brain (basal ganglia), and cornea.
Hepatic parenchymal copper concentration (>250 μg/g dry weight) is the gold standard and definitive diagnostic test for Wilson's disease. Liver biopsy with quantitative copper measurement directly demonstrates pathological copper overload in the hepatic parenchyma, independent of secondary causes that can confound other tests. It is the only test that unambiguously confirms the diagnosis, especially in cases where serum ceruloplasmin is borderline or normal (as can occur in ~5% of patients or in acute liver failure where ceruloplasmin may be falsely elevated as an acute-phase reactant). Major guidelines (EASL, AASLD) designate hepatic copper concentration as the definitive confirmatory test when clinical suspicion is high but non-invasive tests are inconclusive.
While the procedure requires liver biopsy, this is routinely performed in hepatology workup and simultaneously provides histological information about the degree of hepatic injury (steatosis, fibrosis, cirrhosis) — making it doubly informative in a patient already presenting with hepatosplenomegaly and jaundice.
Why other options are wrong
- A. Genetic testing for ATP7B mutation — Confirms the molecular defect but is not the definitive diagnostic test. Over 600 mutations exist in ATP7B, and not all are detectable on standard panels; a negative result does not exclude Wilson's disease. It is reserved for family screening of asymptomatic siblings.
- B. Serum ceruloplasmin — A useful screening test (low in ~85–95% of symptomatic patients, <20 mg/dL), but not definitive. Ceruloplasmin can be falsely normal in acute liver failure or falsely low in protein-losing states, malnutrition, or heterozygous carriers. It is a first-line screening tool, not the gold standard.
- C. Urinary copper — Elevated 24-hour urinary copper (>100 μg/day) supports the diagnosis and is used to monitor treatment response, but it is non-specific (elevated in any cholestatic liver disease) and not definitive on its own.